Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02547428 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: CTN SR
DRUG: Matching placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.